nach oben

Erschienen in:

01.10.2016 | Original Article

The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis

verfasst von: Ons Achour, Sahbi Elmtaoua, Dorsaf Zellama, Asma Omezzine, Amira Moussa, Jihene Rejeb, Imene Boumaiza, Lobna Bouacida, Nabila Ben Rejeb, Abdellatif Achour, Ali Bouslama

Erschienen in: Journal of Nephrology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Hyperhomocysteinaemia, an independent risk factor for cardiovascular diseases, is common in hemodialysis patients (HD) and particularly in those homozygous for polymorphism of the 5,10‐methylenetetrahydrofolate reductase (MTHFR) gene. B vitamins supplementation has been shown to lower plasma total homocysteine (tHcy), but this has been contreversed in several groups. The aim of our study was to explore the response of tHcy in hemodialysis (HD) patients to individual supplementation with folic acid (B9) and/or vitamin B12, based on carrier status for the (MTHFR) polymorphism.

Methods

132HD were randomized according to C677TMTHFR genotypes into 2 groups (AandB). The group (A) was treated initially with B9 (10mg/day orally) for 2 months (t1) and then with B12 vitamin (cyanocobalamin ampoule of 1000 μg) for the following 2 months (t2), then association of B9 and B12 for 2 months (t3). The group (B) was supplemented initially with vitamin B12 (t1), then with folic acid (t2) and then B9 + B12 for 2 months (t3). A wash-out period of 2 months followed the treatment in both groups (t4). We determined tHcy, B9 and B12 concentrations at each time.

Results

In group A, we noted that the decrease in tHcy becomes significant for CC when patients were supplemented with vit B12 only (p = 0.009). While, B9 + vit B12 supplementation did not seem to improve a significant effect compared with B12 alone. For genotypes (CT) and (TT) we noticed a significant decrease in tHcy at t1 (p = 0.038; 0.005 respectively) and at (t3; CT p = 0.024; TT p = 0.017). In group B, for genotypes CC, the decrease in tHcy became significant at t3 (vit B12 + B9; p = 0.031). For genotypes (CT) and (TT), at the replacement of vit B12 by B9, tHcy was significantly decreased (p = 0.036; 0.012, respectively). The combination of the 2 vitamins (t3) showed no difference compared to folate alone. In the 2 groups (t4), there was an significant increase of tHcy again for 3 genotypes.

Conclusion

Supplementation with B vitamins correlated to the MTHFR genotypes has been shown to lower significantly tHcy in HD patients.

Chao MC, Hu SL, Hsu HS, Davidson LE, Lin CH et al (2014) Serum homocysteine level is positively associated with chronic kidney disease in a Taiwan Chinese population. J Nephrol 27(3):299–305

Sen U1, Mishra PK, Tyagi N, Tyagi SC (2010) Homocysteine to hydrogen sulfide or hypertension. Cell Biochem Biophys 57(2–3):49–58

Foley RN, Parfrey PS, Samak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(5 Suppl 3):S112CrossRefPubMed

Brattstrom L, Wilcken DEL (1998) O¨ hrvik J and Brudin L. Common methylentetrahydrofolate reductase gene mutation leads to Hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98:2520–2526CrossRefPubMed

Födinger M, Mannhalter C, Wölfl G, Pabinger I, Muller E, Schmid R et al (1997) Mutation (677 C to T) in the methylentetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52:517–523CrossRefPubMed

Bostom AG, Shemin D, Lapane KL et al (1996) High-dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147–152CrossRefPubMed

Billion S, Tribout B, Cadet E, Queinnec C, Rochette J, Wheatley P et al (2002) Hyperhomocysteinaemia, folate, and vitamin B₁₂ in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B₁₂. Nephrol Dial Transplant 17:455–461CrossRefPubMed

Nair AP, Nemirovsky D, Kim M et al (2005) Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med 72(6):365–373PubMed

Righetti M (2007) Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Clin Chem Lab Med 45:1586–1589CrossRefPubMed

10.

Righetti M, Ferrario GM, Milani S et al (2003) effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 9:137–142

11.

Suliman ME, Stenvinkel P, Heimburger O et al (2002) Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis 40:480–488CrossRefPubMed

12.

Arnadottir M, Gudnason V, Hultberg B (2000) Treatment with different doses of folic acid in haemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant 15:524–528CrossRefPubMed

13.

Weisberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169–172CrossRefPubMed

14.

Sharp L, Little J (2004) Polymorphisms in genes involved in folate metabolism and colorectal neoplasia : a huge review. Am J Epidemiol 159:423–443CrossRefPubMed

15.

Belkahla R, Omezzine A, Kchok K, Rebhi L, Ben Hadj Mbarek I, Rejeb J et al (2008) Effect of polymorphisms on key enzymes in homocysteine metabolism, on plasma homocysteine level and on coronary artery-disease risk in a Tunisian population. Annales de Cardiologie et d’Angéiologie 5(4):219–224

16.

BelhadjMbarek I, Omezzine A, Abroug S, Belkahla R, Rebhi L, Benrejeb N and al. Supplementation in vitamin B response correlated to C 677T MTHFR genotype in hemodialised children. Immuno-analyse et biologie spécialisée (2008)23:368-374

17.

Perna AF, Lanza D, Sepe I, Conzo G, Altucci L, Ingrosso D (2013) Altered folate receptor 2 expression in uraemic patients on haemodialysis: implications for folate resistance. Nephrol Dial Transplant 28(5):1214–1224CrossRefPubMed

18.

Di Daniele N, Di Renzo L, Noce A, Lacopino L, Ferraro FM, Rizzo M et al (2014) Effects of Italian Mediterranean organic diet vs. low-protein diet in nephropathic patients according to MTHFR genotypes. J Nephrol 27(5):529–536

19.

Yong H, Jianping L, Xianhui Q, Yining H, Xiaobin W, Rebecca F et al (2015) Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in China. Am Med Assoc 313:1325–1335

20.

Bostom AG, Shemin D, Bagley P, Massy ZA, Zanabli A, Christopher K et al (2000) Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 101:2829–2832CrossRefPubMed

21.

Dierkes J, Domrose U, Ambrosch A, Schneede J, Guttormsen AB, Neumann KH et al (1999) Supplementation with vitamin B12 decreases homocystein and methylmalonic acid but also serum folate in patients with end stage renal disease. Metabolism 48:631–635CrossRefPubMed

22.

Pastore A, De Angelis S, Casciani S et al (2006) Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes. Clin Chem 52(1):145–148CrossRefPubMed

23.

Tremblay R, Bonnardeaux A, Geadah D et al (2000) Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int 58:851–858CrossRefPubMed

24.

Obeid R, Kuhlmann MK (2005) Ko¨hler H, Herrmann W. Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem 51:196–201CrossRefPubMed

25.

Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang CR, Anderson PH, Seltzer D, Upson B, Lin QR (1997) The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 17:1157–1162CrossRefPubMed

26.

Sunder-Plassmann G, Födinger M, Buchmayer H et al (2000) Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 11:1106–1116PubMed

27.

Azadibakhsh N, Hosseini RS, Atabak S, Nateghiyan N, Golestan B, Rad AH (2009) Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients. Saudi J Kidney Dis Trans 20(5):779–788

28.

Loehrer FM, Haefeli WE, Angst CP et al (1996) Effect of methionine loading on 5 methyltetrahydrofolate, S-adenosylmethionine and Sadenosyl homocysteine in plasma of healthy humans. Clin Sci (Colch) 91:79–86CrossRef

29.

Mansoor MA, Kristensen O, Hervig T et al (1997) Low concentrations of folate in serum and erythrocytes of smokers. Clin Chem 43:2193–2194

30.

Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ (1998) 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 97(3):237–241CrossRefPubMed

31.

Perna AF, D’Aniello A, Lowenson JD, Clarke S, De Santo NG, Ingrosso D (1997) D-aspartate content of erythrocyte membrane proteins is decreased in uremia: implications for the repair of damaged proteins. J Am Soc Nephrol 8:95–104PubMed

32.

Pietrzik K, Bailey L, Shane B (2010) Folic acid and l-5-Methyltetrahydrofolate. Clin Pharmacokinet 49(8):535–548CrossRefPubMed

33.

Litynski P, Loehrer F, Linder L et al (2002) Effect of low dose of 5-methyltetrahydrofolate and folic acid on plasma homocysteine in healthy subjects with or without the 677C-T polymorphism of methylenetetrahydrofolate reductase. Eur J Clin Invest 32:662–668CrossRefPubMed

34.

Fohr IP, Prinz-Langenohl R, Bronstrup A et al (2002) 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Am J Clin Nutr 75(2):275–282PubMed

Titel: The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis
verfasst von: Ons Achour
Sahbi Elmtaoua
Dorsaf Zellama
Asma Omezzine
Amira Moussa
Jihene Rejeb
Imene Boumaiza
Lobna Bouacida
Nabila Ben Rejeb
Abdellatif Achour
Ali Bouslama
Publikationsdatum: 01.10.2016
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 5/2016
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-015-0235-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis